To validate whether the lack of antitumor activity demonstrated by sBCMA-Fc against DLBCL is due to weak binding affinity toward BAFF, we evaluated the binding kinetics of sBCMA to hAPRIL and hBAFF. Here, TNFSF13B is linked to diffuse large B-cell lymphoma.